Every source
The registries, regulators, journals, filings, and feeds Sleuth reads, grouped by what they answer.
Sleuth collects every source below at the source and keeps it current. Each one feeds the records in the knowledge base. Use the filter to find a source by name or region.
166 sources
Clinical trials and registries
Who is running what study, where, and at what stage.
| Source | Region | What it covers |
|---|---|---|
| ClinicalTrials.gov | Global | Trial registrations, status, arms, endpoints, sponsors, sites and posted results |
| WHO ICTRP | Global | Aggregated records from WHO primary registries worldwide |
| EU Clinical Trials Register (EudraCT) | EU | EU trials started before the Clinical Trials Regulation |
| EU CTIS | EU | EU trial applications, decisions and results under the Clinical Trials Regulation |
| ISRCTN | UK | UK primary registry |
| DRKS | EU | German Clinical Trials Register |
| ChiCTR | China | Chinese Clinical Trial Registry |
| China Drug Trial Registration Platform (CDE) | China | Mandatory registration for drug trials in China, often earlier and more complete than ChiCTR for industry trials |
| ITMCTR | China | International Traditional Medicine Clinical Trial Registry, via WHO ICTRP |
| jRCT | Japan | Japan Registry of Clinical Trials |
| ANZCTR | APAC | Australian New Zealand Clinical Trials Registry |
| CTRI | APAC | Clinical Trials Registry – India |
| ReBEC | LatAm | Brazilian Clinical Trials Registry, via WHO ICTRP |
| CRIS | Korea | Korea's Clinical Research Information Service, via WHO ICTRP |
| IRCT | Middle East and Africa | Iranian Registry of Clinical Trials, via WHO ICTRP |
| PACTR | Middle East and Africa | Pan African Clinical Trials Registry, via WHO ICTRP |
| NL-OMON | EU | Overview of Medical Research in the Netherlands, via WHO ICTRP |
| RPCEC | LatAm | Cuban Public Registry of Clinical Trials, via WHO ICTRP |
| REPEC | LatAm | Peruvian Clinical Trials Registry, via WHO ICTRP |
| SLCTR | APAC | Sri Lanka Clinical Trials Registry, via WHO ICTRP |
| TCTR | APAC | Thai Clinical Trials Registry, via WHO ICTRP |
Scientific literature and preprints
What the published science says.
| Source | Region | What it covers |
|---|---|---|
| PubMed / MEDLINE | Global | Biomedical citations and abstracts |
| PubMed Central Open Access | Global | Full-text open-access articles |
| Select peer-reviewed clinical papers | Global | Clinical trial publications beyond PubMed's open-access set |
| Europe PMC | EU | European full text, with links to grants |
| bioRxiv | Global | Biology preprints |
| medRxiv | Global | Clinical and health-science preprints |
| Chinese-language journals, theses, and conference papers | China | Chinese clinical and pharmacology research rarely indexed outside China |
| Crossref | Global | DOI metadata across journals, books and proceedings |
| OpenAlex | Global | Open index of papers, authors and institutions, used for KOL and lab mapping |
Regulatory
What was approved, designated, delayed, or rejected, by which agency.
| Source | Region | What it covers |
|---|---|---|
| FDA drug labels (openFDA / SPL) | US | Prescribing information, indications, boxed warnings |
| DailyMed | US | Current structured product labels from the National Library of Medicine |
| Drugs@FDA | US | Approval history, approval letters and review packages for NDAs and BLAs |
| FDA approval and decision letters | US | Approval letters and agency communications |
| FDA Complete Response Letters | US | Published CRLs explaining why applications were not approved |
| FDA Advisory Committee materials | US | Briefing documents, transcripts, minutes and votes |
| Orange Book | US | Approved small-molecule drugs with patents, exclusivities and therapeutic equivalence |
| Purple Book | US | Licensed biologics, biosimilars, interchangeables and reference product exclusivity |
| CDER Novel Drug Approvals | US | Annual lists of new molecular entities and new biologics |
| CBER approved biologics and cell & gene therapies | US | Vaccines, blood products, cellular and gene therapy approvals |
| FDA Oncology approval notifications (OCE) | US | Oncology and hematology approvals as they happen |
| FDA press announcements | US | Agency news releases |
| Postmarketing Requirements and Commitments | US | Required follow-on studies and their status |
| REMS@FDA | US | Risk evaluation and mitigation strategies |
| FDA guidance documents | US | Draft and final guidance on drug development and review |
| Product-specific guidances | US | Bioequivalence guidance for generics |
| FDA notices in the Federal Register | US | Approval withdrawals, advisory committee notices, exclusivity and user fee notices |
| Orphan Drug Designations and Approvals database | US | Every orphan designation with sponsor, date and indication |
| Breakthrough Therapy designation lists (CDER, CBER) | US | Breakthrough requests granted and resulting approvals |
| Accelerated Approval lists | US | Accelerated approvals, confirmatory trial status and withdrawals |
| RMAT designations (CBER) | US | Regenerative medicine advanced therapy designations |
| Rare Pediatric Disease designations | US | Designations eligible for priority review vouchers |
| Priority review vouchers | US | Vouchers granted, used and sold (rare pediatric, tropical disease, countermeasure) |
| EMA CHMP opinions and meeting highlights | EU | Monthly positive and negative opinions |
| EMA European Public Assessment Reports (EPARs) | EU | Full assessment reports for authorized medicines |
| EC Union Register of medicinal products | EU | EU marketing authorizations and decisions |
| EU orphan designations (Community Register) | EU | Orphan designations by sponsor and condition |
| EMA PRIME | EU | Medicines granted priority medicines support |
| EMA Paediatric Investigation Plans | EU | PIP decisions and waivers |
| EMA withdrawn applications | EU | Applications pulled before an opinion |
| MHRA | UK | UK approvals and product information |
| NMPA | China | Drug and biologic approvals and announcements |
| CDE | China | IND acceptances, priority review, breakthrough therapy and conditional approval lists; review reports |
| PMDA | Japan | Approvals list and review reports |
| MHLW designations | Japan | Sakigake, orphan and conditional approval designations |
| Health Canada Drug Product Database | Canada | Drugs marketed in Canada |
| Health Canada Notice of Compliance database | Canada | Canadian approvals, including conditional NOCs |
| TGA Australian Register of Therapeutic Goods (ARTG) | APAC | Australian registrations |
| TGA Australian Public Assessment Reports (AusPARs) | APAC | Public assessment reports for Australian approvals |
| Project Orbis | Global | FDA-led concurrent review of cancer drugs with partner agencies |
| Access Consortium | Global | Work-sharing reviews by the UK, Canada, Australia, Singapore, and Switzerland |
Safety and pharmacovigilance
What safety signals exist after approval.
| Source | Region | What it covers |
|---|---|---|
| FAERS (via openFDA) | US | Adverse event reports for drugs and therapeutic biologics |
| FDA Drug Safety-related Labeling Changes (SrLC) | US | Label safety updates by drug and date |
| FDA Drug Safety Communications | US | Agency safety notices by drug |
| MedWatch safety alerts | US | FDA safety alerts for drugs and biologics |
| VAERS | US | Vaccine adverse event reports |
| EudraVigilance (adrreports.eu) | EU | Suspected adverse reaction reports in the EU |
| EMA PRAC signals and meeting highlights | EU | Safety signals under EU review |
| WHO VigiAccess | Global | Public view of the WHO global safety database |
Clinical guidelines and standard of care
How patients are treated today.
| Source | Region | What it covers |
|---|---|---|
| HHS HIV guidelines | US | Treatment guidelines: HIV |
| ACIP (CDC) | US | Treatment guidelines: vaccines |
| Clinical practice guidelines from major medical societies | Global | Treatment guidelines across therapy areas |
Epidemiology and public health
How many patients there are.
| Source | Region | What it covers |
|---|---|---|
| SEER | US | US cancer incidence, prevalence and survival |
| CDC WONDER | US | US mortality and disease data |
| NHANES (NCHS) | US | US national health and nutrition survey: obesity, diabetes, hypertension, and more |
| NHIS (NCHS) | US | US national health interview survey |
| Eurostat health database | EU | EU health and causes-of-death data |
| European Cancer Information System (ECIS) | EU | EU cancer estimates by country |
| China CDC | China | Chinese disease surveillance and reports |
| China National Cancer Center | China | Annual Chinese cancer statistics |
| WHO Global Health Observatory | Global | Global health indicators |
| OECD Health Statistics | Global | Health and disease data for OECD countries |
| Orphanet prevalence data | Global | Rare disease prevalence and incidence |
| UN World Population Prospects | Global | Population by age and country |
Pricing, reimbursement, and HTA
What a drug costs, and whether it gets paid for.
| Source | Region | What it covers |
|---|---|---|
| CMS ASP pricing files | US | Medicare Part B average sales prices |
| NADAC (Medicaid) | US | National average pharmacy acquisition costs by drug |
| Medicaid State Drug Utilization Data | US | Medicaid prescriptions by drug and state |
| Medicare Part D Spending Dashboard | US | Medicare Part D spend and claims by drug |
| Medicare Part B Spending Dashboard | US | Medicare Part B spend and claims by drug |
| Medicare Drug Price Negotiation | US | Drugs selected under the Inflation Reduction Act and negotiated prices |
| NICE technology appraisals | UK | England reimbursement decisions |
| G-BA (AMNOG) | EU | German benefit decisions that set pricing |
| IQWiG (AMNOG) | EU | German benefit assessments behind G-BA decisions |
| HAS Transparency Committee | EU | French benefit ratings |
| EU Joint Clinical Assessments | EU | EU-wide HTA under the 2025 regulation |
| China National Reimbursement Drug List (NHSA) | China | NRDL listings and negotiated prices |
| Japan NHI price listings | Japan | Japanese reimbursement prices |
Patents and IP
Who owns what, and when exclusivity ends.
| Source | Region | What it covers |
|---|---|---|
| US Patent and Trademark Office | US | US patents and applications |
| European Patent Office | EU | European patents and applications |
| Japan Patent Office | Japan | Japanese patents and applications |
| China National Intellectual Property Administration | China | Chinese patents and applications |
| WIPO PCT applications | Global | International applications, often the first filing on a new program |
| Orange Book patents and exclusivities | US | Listed patents and exclusivity expiry per drug |
| Paragraph IV certifications list | US | Drugs facing generic patent challenges |
| Purple Book patent lists | US | Biologic patents disclosed in biosimilar litigation |
Company filings and disclosures
What companies are required to disclose.
| Source | Region | What it covers |
|---|---|---|
| SEC EDGAR | US | 10-K, 10-Q, 8-K, S-1, F-1, 20-F, 6-K and proxy filings |
| SEC exhibits (license and collaboration agreements) | US | Filed deal agreements with economics and terms |
| SEC ownership filings (13D, 13G, 13F) | US | Activist stakes and institutional holdings |
| SEC Form D | US | Private placements and venture rounds |
| HKEXnews | China | Hong Kong listings, including 18A biotech prospectuses and announcements |
| CNInfo | China | Shanghai and Shenzhen disclosures, including STAR Market biotechs |
| EDINET | Japan | Japanese securities filings |
| TDnet | Japan | Japanese timely disclosures |
| DART | Korea | Korean securities filings |
Company websites and investor materials
What companies choose to say.
| Source | Region | What it covers |
|---|---|---|
| Company pipeline pages | Global | Programs, targets, modalities and phases as companies list them, public and private |
| Company press releases | Global | Releases posted on company newsrooms |
| Corporate and investor presentations | Global | Pipeline decks and corporate overviews |
| Earnings call transcripts | Global | Management commentary and analyst Q&A |
| Investor day and R&D day materials | Global | Slides and transcripts from strategy events |
| Healthcare investor conference presentations | Global | Fireside chats and presentations at bank-hosted investor conferences and JPM week |
| Corporate brochures and white papers | Global | Company-issued technical and platform documents |
| Posters and publications hosted on company sites | Global | Scientific posters companies post after meetings |
| Company-hosted KOL events | Global | Webcasts with key opinion leaders |
| Archived versions of company pages | Global | Historical versions of pipeline pages, showing what was dropped or changed |
| Public market data | Global | Share prices and market caps for listed companies, from public web sources |
News and newswires
What happened this week.
| Source | Region | What it covers |
|---|---|---|
| Business Wire | Global | Company press releases |
| PR Newswire | Global | Company press releases |
| GlobeNewswire | Global | Company press releases |
| Biotech and pharma trade press | Global | Daily industry news on approvals, readouts, deals, and financings |
Research funding and grants
What academic science is funded before it becomes a company.
| Source | Region | What it covers |
|---|---|---|
| NIH RePORTER | US | NIH-funded projects, investigators and linked papers |
| ARPA-H | US | US advanced health research programs and awards |
| SBIR / STTR awards | US | US small business innovation grants to biotechs |
| EU CORDIS | EU | Horizon Europe and ERC projects |
Biology and disease reference data
Public reference sets used alongside Sleuth's own ontology.
| Source | Region | What it covers |
|---|---|---|
| Disease Ontology | Global | Disease classification |
| MONDO | Global | Unified disease ontology, strong on rare disease |
| MeSH | Global | NLM's controlled vocabulary used across PubMed |
| ICD-10-CM | US | US diagnosis codes |
| ICD-11 | Global | WHO international diagnosis codes |
| NCI Thesaurus | US | Cancer terminology and drug names |
| Orphanet nomenclature | Global | Rare disease names, genes and classifications |
| Open Targets | Global | Target–disease evidence |
| UniProt | Global | Protein sequences and function |
| HGNC | Global | Official gene names |
| NCBI Gene | Global | Gene records |
| Ensembl | Global | Genome annotation |
| Human Protein Atlas | Global | Tissue and cell expression |
| ChEMBL | Global | Bioactive molecules and assay data |
| IUPHAR/BPS Guide to Pharmacology | Global | Targets and ligands |
| PubChem | Global | Chemical structures and bioactivity |
| FDA Global Substance Registration System (UNII) | US | Unique substance identifiers |
| RxNorm | US | Normalized US drug names |
Social and alternative signals
Early signals outside formal disclosure.
| Source | Region | What it covers |
|---|---|---|
| WeChat official accounts | China | Pipeline, financing and trial updates from Chinese biotechs, translated |
| Company job postings | Global | Hiring by function and site, an early read on program and commercial build-out |
| People and executive moves | Global | Leadership changes and team build-outs |
| Social posts from companies, KOLs, and analysts | Global | Real-time commentary around data releases and meetings |
| Biotech podcasts and webinars | Global | Executive and investor interviews, transcribed |
Medical meetings
Abstracts, posters, oral presentation slides, and late-breakers from about 365 medical meetings across 20 therapy areas, with archives back to 2015, including China-focused meetings.
Sell-side research
Research from 35+ banks and brokers. Sell-side research
Don't see a source you need?
Sleuth adds sources when customers need them. Tell us which one
Updated November 9, 2026